BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 31369115)

  • 1. Effect of concomitant vancomycin and piperacillin-tazobactam on frequency of acute kidney injury in pediatric patients.
    Buhlinger KM; Fuller KA; Faircloth CB; Wallace JR
    Am J Health Syst Pharm; 2019 Aug; 76(16):1204-1210. PubMed ID: 31369115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of Acute Kidney Injury Among Patients Receiving the Combination of Vancomycin with Piperacillin-Tazobactam or Meropenem.
    Robertson AD; Li C; Hammond DA; Dickey TA
    Pharmacotherapy; 2018 Dec; 38(12):1184-1193. PubMed ID: 30175410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children.
    Downes KJ; Cowden C; Laskin BL; Huang YS; Gong W; Bryan M; Fisher BT; Goldstein SL; Zaoutis TE
    JAMA Pediatr; 2017 Dec; 171(12):e173219. PubMed ID: 28973124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and Risk Factors of Acute Kidney Injury in Patients Receiving Concomitant Vancomycin and Continuous-Infusion Piperacillin/Tazobactam: A Retrospective Cohort Study.
    Blair K; Covington EW
    Ann Pharmacother; 2020 Nov; 54(11):1096-1101. PubMed ID: 32406243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risk of Acute Kidney Injury in Patients Treated with Vancomycin and Piperacillin/Tazobactam Compared to Vancomycin and Meropenem or Doripenem: A Retrospective Cohort Study].
    Ide N; Sato S; Sawaguchi K
    Yakugaku Zasshi; 2019; 139(12):1609-1614. PubMed ID: 31787651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk and Time-to-Onset of Acute Kidney Injury With Vancomycin Plus Piperacillin-tazobactam Combination: Analysis Using JADER.
    Ide N; Sako KI; Takigawa M; Tanaka H
    In Vivo; 2024; 38(3):1436-1442. PubMed ID: 38688650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship.
    Karino S; Kaye KS; Navalkele B; Nishan B; Salim M; Solanki S; Pervaiz A; Tashtoush N; Shaikh H; Koppula S; Martin ET; Mynatt RP; Murray KP; Rybak MJ; Pogue JM
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3743-50. PubMed ID: 27067325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute Kidney Injury in Hematopoietic Cell Transplantation Patients Receiving Vancomycin and Piperacillin/Tazobactam Versus Vancomycin and Cefepime.
    Clemmons AB; Bech CF; Pantin J; Ahmad I
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):820-826. PubMed ID: 29292056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of area under the concentration-time curve-guided vancomycin dosing with or without piperacillin-tazobactam on the incidence of acute kidney injury.
    Muklewicz JD; Steuber TD; Edwards JD
    Int J Antimicrob Agents; 2021 Jan; 57(1):106234. PubMed ID: 33232734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of total body weight on rate of acute kidney injury in patients treated with piperacillin-tazobactam and vancomycin.
    Rutter WC; Hall RG; Burgess DS
    Am J Health Syst Pharm; 2019 Aug; 76(16):1211-1217. PubMed ID: 31369116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased Risk of Acute Kidney Injury in Critically Ill Children Treated With Vancomycin and Piperacillin/Tazobactam.
    Holsen MR; Meaney CJ; Hassinger AB; Fusco NM
    Pediatr Crit Care Med; 2017 Dec; 18(12):e585-e591. PubMed ID: 28906422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime.
    Navalkele B; Pogue JM; Karino S; Nishan B; Salim M; Solanki S; Pervaiz A; Tashtoush N; Shaikh H; Koppula S; Koons J; Hussain T; Perry W; Evans R; Martin ET; Mynatt RP; Murray KP; Rybak MJ; Kaye KS
    Clin Infect Dis; 2017 Jan; 64(2):116-123. PubMed ID: 27986669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative incidence and excess risk of acute kidney injury in hospitalised patients receiving vancomycin and piperacillin/tazobactam in combination or as monotherapy.
    Carreno J; Smiraglia T; Hunter C; Tobin E; Lomaestro B
    Int J Antimicrob Agents; 2018 Nov; 52(5):643-650. PubMed ID: 30103003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
    Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K
    Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combinatorial Vancomycin and Piperacillin/Tazobactam Results in Elevated Vancomycin Trough Concentration and Acute Kidney Injury: A Case Report].
    Sakai Y; Miwa R; Mitsuoka M; Watanabe H
    Yakugaku Zasshi; 2020; 140(5):751-754. PubMed ID: 32378679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study.
    Miano TA; Hennessy S; Yang W; Dunn TG; Weisman AR; Oniyide O; Agyekum RS; Turner AP; Ittner CAG; Anderson BJ; Wilson FP; Townsend R; Reilly JP; Giannini HM; Cosgriff CV; Jones TK; Meyer NJ; Shashaty MGS
    Intensive Care Med; 2022 Sep; 48(9):1144-1155. PubMed ID: 35833959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Risk of Acute Kidney Injury in Critically Ill Patients Receiving Concomitant Vancomycin With Piperacillin-Tazobactam or Cefepime.
    Molina KC; Barletta JF; Hall ST; Yazdani C; Huang V
    J Intensive Care Med; 2020 Dec; 35(12):1434-1438. PubMed ID: 30741072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective Cohort Study of the Incidence of Acute Kidney Injury with Vancomycin Area under the Curve-Based Dosing with Concomitant Piperacillin-Tazobactam Compared to Meropenem or Cefepime.
    Kiley PS; Pearston AP; Hodge LA; Kaplan MC; Baczek SM; Stanley JS; Wilson TJ; Soriano KM; Yao A; Shaeffer ZA; Talt IE; Cohen JA; Ingemi AI
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0004022. PubMed ID: 35867523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of acute kidney injury risk associated with vancomycin and concomitant piperacillin/tazobactam or cefepime in the intensive care unit.
    Buckley MS; Hartsock NC; Berry AJ; Bikin DS; Richards EC; Yerondopoulos MJ; Kobic E; Wicks LM; Hammond DA
    J Crit Care; 2018 Dec; 48():32-38. PubMed ID: 30172962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam.
    Burgess LD; Drew RH
    Pharmacotherapy; 2014 Jul; 34(7):670-6. PubMed ID: 24855041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.